The transcription factor GATA-4 regulates cytochrome P4502C19 gene expression

Life Sciences

Volumn 86, Issue 19-20, 2010, Pages 699-706

  Mwinyi, Jessica ^a   Hofmann, Yvonne ^a   Pedersen, Rasmus Steen ^a   Nekvindová, Jana ^a   Cavaco, Isa ^a   Mkrtchian, Souren ^a   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

CYP2C19; Drug metabolism; Escitalopram; FOG 2; GATA; Omeprazole; Promoter mediated regulation

Indexed keywords

CYTOCHROME P450 2C19; LUCIFERASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOG 2; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR GATA 4; UNCLASSIFIED DRUG; CYP2C19 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CELL STRAIN HEPG2; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EXPRESSION VECTOR; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC TRANSFECTION; GENETIC VARIABILITY; GENOMIC FRAGMENT; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN BINDING; PROTEIN INTERACTION; REPORTER GENE; SEQUENCE ANALYSIS; UPREGULATION; ANIMAL; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOUSE; MUTATION; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BINDING SITES; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GATA2 TRANSCRIPTION FACTOR; GATA4 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEP G2 CELLS; HUMANS; LUCIFERASES; MICE; MUTATION; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC;

EID: 77951914218     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.02.021     Document Type: Article

References (39)

1. Arefayene M., Skaar T.C., Zhao X., Rae J.M., Tanus-Santos J.E., Brinkmann U., Brehm I., Salat U., Nguyen A., Desta Z., Flockhart D.A. Sequence diversity and functional characterization of the 5'-regulatory region of human CYP2C19. Pharmacogenetics 2003, 13(4):199-206.
2. Baldwin R.M., Ohlsson S., Pedersen R.S., Mwinyi J., Ingelman-Sundberg M., Eliasson E., Bertilsson L. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. British Journal of Clinical Pharmacology 2008, 65(5):767-774.
3. Bort R., Gomez-Lechon M.J., Castell J.V., Jover R. Role of hepatocyte nuclear factor 3 gamma in the expression of human CYP2C genes. Archives of Biochemistry and Biophysics 2004, 426(1):63-72.
4. Bossard P., Zaret K.S. GATA transcription factors as potentiators of gut endoderm differentiation. Development 1998, 125(24):4909-4917.
5. Bulyk M.L., Johnson P.L., Church G.M. Nucleotides of transcription factor binding sites exert interdependent effects on the binding affinities of transcription factors. Nucleic Acids Research 2002, 30(5):1255-1261.
6. Chang M., Dahl M.L., Tybring G., Gotharson E., Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995, 5(6):358-363.
7. Chen Y., Ferguson S.S., Negishi M., Goldstein J.A. Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Molecular Pharmacology 2003, 64(2):316-324.
8. Crispino J.D., Lodish M.B., Thurberg B.L., Litovsky S.H., Collins T., Molkentin J.D., Orkin S.H. Proper coronary vascular development and heart morphogenesis depend on interaction of GATA-4 with FOG cofactors. Genes and Development 2001, 15(7):839-844.
9. Dame C., Sola M.C., Lim K.C., Leach K.M., Fandrey J., Ma Y., Knopfle G., Engel J.D., Bungert J. Hepatic erythropoietin gene regulation by GATA-4. Journal of Biological Chemistry 2004, 279(4):2955-2961.
10. Dignam J.D., Lebovitz R.M., Roeder R.G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Research 1983, 11(5):1475-1489.
11. Fukushima-Uesaka H., Saito Y., Maekawa K., Ozawa S., Hasegawa R., Kajio H., Kuzuya N., Yasuda K., Kawamoto M., Kamatani N., Suzuki K., Yanagawa T., Tohkin M., Sawada J. Genetic variations and haplotypes of CYP2C19 in a Japanese population. Drug Metabolism and Pharmacokinetics 2005, 20(4):300-307.
12. Herrlin K., Massele A.Y., Rimoy G., Alm C., Rais M., Ericsson O., Bertilsson L., Gustafsson L.L. Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype. Clinical Pharmacology and Therapeutics 2000, 68(2):189-198.
13. Hirai M., Ono K., Morimoto T., Kawamura T., Wada H., Kita T., Hasegawa K. FOG-2 competes with GATA-4 for transcriptional coactivator p300 and represses hypertrophic responses in cardiac myocytes. Journal of Biological Chemistry 2004, 279(36):37640-37650.
14. Hung H.L., Pollak E.S., Kudaravalli R.D., Arruda V., Chu K., High K.A. Regulation of human coagulation factor X gene expression by GATA-4 and the Sp family of transcription factors. Blood 2001, 97(4):946-951.
15. Ingelman-Sundberg M., Sim S.C., Gomez A., Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacology and Therapeutics 2007, 116(3):496-526.
16. Kawashima S., Kobayashi K., Takama K., Higuchi T., Furihata T., Hosokawa M., Chiba K. Involvement of hepatocyte nuclear factor 4alpha in the different expression level between CYP2C9 and CYP2C19 in the human liver. Drug Metabolism and Disposition 2006, 34(6):1012-1018.
17. Kirchheiner J., Nickchen K., Bauer M., Wong M.L., Licinio J., Roots I., Brockmoller J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Molecular Psychiatry 2004, 9(5):442-473.
18. Klose T.S., Blaisdell J.A., Goldstein J.A. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. Journal of Biochemical and Molecular Toxicology 1999, 13(6):289-295.
19. Klotz U., Schwab M., Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic and Clinical Pharmacology and Toxicology 2004, 95(1):2-8.
20. Kwintkiewicz J., Cai Z., Stocco C. Follicle-stimulating hormone-induced activation of Gata4 contributes in the up-regulation of Cyp19 expression in rat granulosa cells. Molecular Endocrinology 2007, 21(4):933-947.
21. Lapple F., von Richter O., Fromm M.F., Richter T., Thon K.P., Wisser H., Griese E.U., Eichelbaum M., Kivisto K.T. Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics 2003, 13(9):565-575.
22. Lin A.C., Roche A.E., Wilk J., Svensson E.C. The N termini of Friend of GATA (FOG) proteins define a novel transcriptional repression motif and a superfamily of transcriptional repressors. Journal of Biological Chemistry 2004, 279(53):55017-55023.
23. Lu J.R., McKinsey T.A., Xu H., Wang D.Z., Richardson J.A., Olson E.N. FOG-2, a heart- and brain-enriched cofactor for GATA transcription factors. Molecular and Cellular Biology 1999, 19(6):4495-4502.
24. Molkentin J.D. The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression. Journal of Biological Chemistry 2000, 275(50):38949-38952.
25. Nakabayashi H., Hashimoto T., Miyao Y., Tjong K.K., Chan J., Tamaoki T. A position-dependent silencer plays a major role in repressing alpha-fetoprotein expression in human hepatoma. Molecular and Cellular Biology 1991, 11(12):5885-5893.
26. Ohneda K., Yamamoto M. Roles of hematopoietic transcription factors GATA-1 and GATA-2 in the development of red blood cell lineage. Acta Haematologica 2002, 108(4):237-245.
27. Peterkin T., Gibson A., Loose M., Patient R. The roles of GATA-4, -5 and -6 in vertebrate heart development. Seminars in Cell and Developmental Biolology 2005, 16(1):83-94.
28. Peterkin T., Gibson A., Patient R. GATA-6 maintains BMP-4 and Nkx2 expression during cardiomyocyte precursor maturation. Embo Journal 2003, 22(16):4260-4273.
29. Rudberg I., Mohebi B., Hermann M., Refsum H., Molden E. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Molecular Therapy 2008, 83(2):322-327.
30. Shadley J.D., Divakaran K., Munson K., Hines R.N., Douglas K., McCarver D.G. Identification and functional analysis of a novel human CYP2E1 far upstream enhancer. Molecular Pharmacology 2007, 71(6):1630-1639.
31. Sim S.C., Risinger C., Dahl M.L., Aklillu E., Christensen M., Bertilsson L., Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clinical Pharmacology and Therapeutics 2006, 79(1):103-113.
32. Sumi K., Tanaka T., Uchida A., Magoori K., Urashima Y., Ohashi R., Ohguchi H., Okamura M., Kudo H., Daigo K., Maejima T., Kojima N., Sakakibara I., Jiang S., Hasegawa G., Kim I., Osborne T.F., Naito M., Gonzalez F.J., Hamakubo T., Kodama T., Sakai J. Cooperative interaction between hepatocyte nuclear factor 4 alpha and GATA transcription factors regulates ATP-binding cassette sterol transporters ABCG5 and ABCG8. Molecular and Cellular Biology 2007, 27(12):4248-4260.
33. Svensson E.C., Huggins G.S., Dardik F.B., Polk C.E., Leiden J.M. A functionally conserved N-terminal domain of the friend of GATA-2 (FOG-2) protein represses GATA4-dependent transcription. Journal of Biological Chemistry 2000, 275(27):20762-20769.
34. Svensson E.C., Tufts R.L., Polk C.E., Leiden J.M. Molecular cloning of FOG-2: a modulator of transcription factor GATA-4 in cardiomyocytes. Proceedings of the National Academy of Sciences of the United States of America 1999, 96(3):956-961.
35. Temsah R., Nemer M. GATA factors and transcriptional regulation of cardiac natriuretic peptide genes. Regulatory Peptides 2005, 128(3):177-185.
36. Tsang A.P., Visvader J.E., Turner C.A., Fujiwara Y., Yu C., Weiss M.J., Crossley M., Orkin S.H. FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. Cell 1997, 90(1):109-119.
37. Yin O.Q., Tomlinson B., Chow A.H., Waye M.M., Chow M.S. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability. Journal of Clinical Pharmacology 2004, 44(6):582-589.
38. Zhang H., Cui D., Wang B., Han Y.H., Balimane P., Yang Z., Sinz M., Rodrigues A.D. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clinical Pharmacokinetics 2007, 46(2):133-157.
39. Zhu Q.S., Qian B., Levy D. Regulation of human microsomal epoxide hydrolase gene (EPHX1) expression by the transcription factor GATA-4. Biochimica et Biophysica Acta 2004, 1676(3):251-260.